Why Most Foreign Healthcare Companies Quietly Fail in BrazilEven with distributors, competitive pricing, and ANVISA approval.
Because the real problem is rarely the product —
it's the structure behind the market entry.
Watch the Strategic Briefing
A concise executive overview explaining why most international healthcare companies struggle to scale in Brazil.
Executive Framework 01
Entering Brazil Is Easy.
Scaling Brazil Is Different.
Most healthcare companies focus on entering Brazil.
But few focus on building a structure truly capable of scaling their business.
Executive Insight 02
Brazil Is Not Difficult.
It Is Structurally Different.
Approval does not create demand.
Access does not guarantee execution.
Lower prices do not automatically create adoption.
Relationships matter as much as products.
Growth is often determined before the first sale.
Visibility drives decision quality.
The companies that succeed in Brazil usually have better connections and market structures — not necessarily better products.
Strategic Diagnostic 03
The Real Risk Isn't Lack Of Information.
It is the confidence built on incomplete signals and misleading information.
- 01Information
- 02Contacts
- 03Meetings
- 04Confidence
- 05Wrong Conclusions
- 06Costly Decisions
False Clarity
When information creates confidence before understanding exists.
The Invisible Problem 04
The Distributor Savior Illusion
01
Company
02
Distributor
03
Market
What Is Lost Along The Way
Loss of
Control
Loss of
Visibility
Loss of
Data
Loss of
Feedback
Loss of
Strategic Flexibility
What initially appears to simplify market entry often becomes the primary limitation to sustainable growth.
LINK Healthcare Method 05
Control Architecture
The five structural pillars behind every successful Brazil market entry.
Product Registration
Market Access
Channel Strategy
Positioning
Execution
Segmentation 06
Who We Help
Preparing to Enter Brazil
You are evaluating Brazil, or preparing to enter. The decisions made in the next 90 days — registration path, channel structure, pricing architecture — will define what is possible for the next three years. Most of them get made on incomplete signals.
- Pre-entry structural diagnostic
- Distributor evaluation framework
- ANVISA and pricing strategy
Already in Brazil, Structure Limiting Growth
You have ANVISA approval, a distributor, competitive pricing — and the numbers are not moving. The problem is rarely the product or the market. It is the structure standing between you and the customer.
- Operational and channel structure audit
- Distributor performance and dependency review
- 90-day growth unblock plan
Authority
Built On Decades Inside Brazilian Healthcare Market
25+
Years
Healthcare Market Experience
100
Most Influential
Brazilian Healthcare
Top 100
Of The Decade
Brazilian Healthcare
Global
Companies Served
International Healthcare
Ronald Lorentziadis
Founder · LINK Healthcare
Elected among the 100 Most Influential of the Decade in Brazilian Healthcare. Trusted by international healthcare companies entering and scaling in Brazil.
Connect on LinkedInInternational Healthcare Companies Served
Executive Briefing
Brazil Fit Call
A confidential 30-minute conversation with Ronald Lorentziadis to establish whether your situation in Brazil is one we are positioned to solve — and whether we are the right firm to solve it.
You will leave knowing which of the five structural pillars is most likely constraining you, and what a rigorous assessment of your operation would involve.
This is not a market assessment. Analysis and recommendations specific to your operation are the output of a paid engagement.
Reserved for executives with decision authority evaluating a move within the next 12 months.
Topics Covered
Periodic Briefings
Executive Insights & Strategic Briefings
Receive periodic perspectives on the Brazilian healthcare market.
Request a Brazil Fit Call
Fix the structure first.
Scale your business in Brazil with clarity, control, and strategic alignment.
FAQ
Frequently Asked Questions
Brazil Fit Call
Request a Brazil Fit Call